Mutation of TP53 and alteration of p14arf expression in EGFR- and KRAS-Mutated lung adenocarcinomas

Clinical Lung Cancer

Volumn 15, Issue 2, 2014, Pages 124-130

  Cortot, Alexis B ^a,b,c   Younes, Mohamad ^a,d   Martel Planche, Ghislaine ^a   Guibert, Benoit ^b   Isaac, Sylvie ^b   Souquet, Pierre Jean ^b   Commo, Frédéric ^e,f   Girard, Philippe ^g   Fouret, Pierre ^b,e   Brambilla, Elisabeth ^h   Hainaut, Pierre ^a,i   Soria, Jean Charles ^e,f  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Universite Paris Sud   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

^h HÔPITAL MICHALLON   (France)

ⁱ INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

EGFR; KRAS; Lung adenocarcinoma; p14arf; p53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P53; RAS PROTEIN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; AGED; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894037427     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.08.003     Document Type: Article

References (28)

1. L. Ding, G. Getz, and D.A. Wheeler et al. Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
2. T.S. Mok, Y.-L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
3. Z. Chen, K. Cheng, and Z. Walton et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 483 2012 613 617
4. P.A. Janne, A.T. Shaw, and J.R. Pereira et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) J Clin Oncol 30 suppl 2012 abstract 7503
5. M. Hollstein, D. Sidransky, and B. Vogelstein et al. p53 mutations in human cancers Science 253 1991 49 53
6. M. Lomazzi, M.C. Moroni, and M.R. Jensen et al. Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry Nat Genet 31 2002 190 194
7. P. Ozenne, B. Eymin, and E. Brambilla et al. The ARF tumor suppressor: structure, functions and status in cancer Int J Cancer 127 2010 2239 2247
8. N.E. Sharpless INK4a/ARF: a multifunctional tumor suppressor locus Mutat Res 576 2005 22 38
9. H.-S. Hsu, Y.-C. Wang, and R.-C. Tseng et al. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer Clin Cancer Res 10 2004 4734 4741
10. M. Mounawar, A. Mukeria, and F. Le Calvez et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history Cancer Res 67 2007 5667 5672
11. P. Ozenne, D. Dayde, and E. Brambilla et al. p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway Oncogene 32 2013 1050 1058
12. F. Le Calvez, A. Mukeria, and J.D. Hunt et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers Cancer Res 65 2005 5076 5083
13. P. Anker, F. Lefort, and V. Vasioukhin et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer Gastroenterology 112 1997 1114 1120
14. W. Pao, V. Miller, and M. Zakowski et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
15. G.P. Pfeifer, M.F. Denissenko, and M. Olivier et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers Oncogene 21 2002 7435 7451
16. S. Gazzeri, V. Della Valle, and L. Chaussade et al. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer Cancer Res 58 1998 3926 3931
17. B. Job, A. Bernheim, and M. Beau-Faller et al. Genomic aberrations in lung adenocarcinoma in never smokers PLoS ONE 5 2010 e15145
18. T. Kosaka, Y. Yatabe, and H. Endoh et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 2006 5764 5769
19. D.B. Costa, B. Halmos, and A. Kumar et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations PLoS Med 4 2007 1669 1679 discussion 1680
20. M.S. Cragg, J. Kuroda, and H. Puthalakath et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med 4 2007 1681 1689 discussion 1690
21. Y. Gong, R. Somwar, and K. Politi et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas PLoS Med 4 2007 e294
22. R. Rosell, B. Massuti, and C. Costa et al. Concomitant actionable mutations and overall survival in EGFR-mutant non-small-cell lung cancer patients included in the EURTAC trialâ€̄: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3) Ann Oncol 23 2012 abstract LBA 31
23. H.-G. Wendel, E. De Stanchina, and E. Cepero et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition Proc Natl Acad Sci U S A 103 2006 7444 7449
24. S. Bouali, A.-S. Chrétien, and C. Ramacci et al. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab Cancer Gene Ther 16 2009 498 507
25. J.K. Rho, Y.J. Choi, and B.-Y. Ryoo et al. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer Cancer Res 67 2007 1163 1169
26. R. Rosell, T. Moran, and C. Queralt et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
27. T. Kosaka, Y. Yatabe, and R. Onozato et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol 4 2009 22 29
28. G. Jin, M.J. Kim, and H.-S. Jeon et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers Lung Cancer 69 2010 279 283